Matinas BioPharma Prices $10 Million Registered Direct Offering
- None.
- None.
The direct offering by Matinas BioPharma to sell over 33 million shares, including equal warrants, at a price considerably lower than typical market value, can be indicative of several strategic maneuvers. Firstly, the capital raised, approximately $10 million before expenses, may signal an urgent need for liquidity to fund ongoing research and development or to maintain operations. This is a common approach for clinical-stage biopharmaceutical companies that are not yet generating revenue from product sales.
Investors should consider the dilutive effect of such an offering on current shareholders. Adding over 33 million shares will spread the company's earnings (or losses) across a greater number of shares, potentially reducing the value of existing shares. However, if the funds are used effectively to advance the LNC platform delivery technology and bring a product to market, there could be long-term benefits.
Moreover, the warrant exercise price set at $0.35 suggests an anticipated increase in share value, providing an opportunity for investors to capitalize on future growth. However, the timeframe until exercise and the expiration of the warrants should be considered when assessing the risk and potential reward of this investment.
Matinas BioPharma's use of its lipid nanocrystal (LNC) platform is a key factor to consider. LNC technology represents a novel approach in drug delivery, potentially overcoming limitations of traditional methods by enhancing the bioavailability of drugs. The success of such technologies can disrupt markets and create new therapeutic possibilities.
However, the biopharmaceutical industry is highly competitive and the road from clinical-stage to market is fraught with regulatory and clinical trial challenges. The approximate $10 million raise might seem modest in comparison to the high costs associated with bringing a drug through to FDA approval and commercialization. This raises questions about the company's long-term funding strategy and whether additional capital will be required.
Investors should examine the company's pipeline and the potential market for its products. If the LNC technology proves successful and applicable to a range of drugs, it could open up significant market opportunities. On the flip side, any setbacks in clinical trials or regulatory processes could adversely affect the company's prospects and stock value.
From a legal perspective, the structure of the securities purchase agreements warrants attention. The offering being registered directly rather than through an underwriter can expedite the process and reduce costs for Matinas BioPharma. However, it also places a greater onus on the company to ensure compliance with securities laws and regulations.
The terms of the warrants, including the exercise price and expiration period, must be scrutinized to ensure they align with investor protections and market standards. Investors should be aware of their rights under these warrants and any potential implications for their investment, such as the possibility of future dilution if the warrants are exercised and additional shares are introduced to the market.
It is also important to consider the timing of the offering's closure and any conditions that must be met. Delays or complications could impact the company's access to the needed funds and potentially affect its operational plans.
BEDMINSTER, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) (“Matinas BioPharma” or the “Company”), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, today announced it has entered into securities purchase agreements with healthcare-focused institutional investors for the purchase and sale of 33,333,334 shares of common stock, par value
The gross proceeds of the offering will be approximately
A.G.P./Alliance Global Partners is acting as sole placement agent for the offering.
This offering was made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-272580) previously filed with the U.S. Securities and Exchange Commission (the “SEC”) and was declared effective on June 20, 2023. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. A final prospectus supplement and accompanying base prospectus relating to the offering will be filed by Matinas BioPharma with the SEC. When available, copies of the prospectus supplement, together with the accompanying prospectus, can be obtained at the SEC’s website at www.sec.gov or from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, New York 10022 or by e-mail at Investmentbanking@allianceg.com.
About Matinas BioPharma
Matinas BioPharma is a biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology.
Matinas’ lead LNC-based therapy is MAT2203, an oral formulation of the broad-spectrum antifungal drug amphotericin B, which although highly potent, can be associated with significant toxicity. Matinas’ LNC platform provides oral delivery of amphotericin B without the significant nephrotoxicity otherwise associated with IV-delivered formulations. Combining comparable fungicidal activity with targeted delivery results in a lower risk of toxicity and potentially creates the ideal antifungal agent for the treatment of invasive fungal infections. MAT2203 was successfully evaluated in the completed Phase 2 EnACT study in HIV patients suffering from cryptococcal meningitis, meeting its primary endpoint and achieving robust survival. MAT2203 will be further evaluated in a single Phase 3 registration trial (the “ORALTO” trial) as an oral step-down monotherapy following treatment with AmBisome® (liposomal amphotericin B) compared with the standard of care in patients with invasive aspergillosis who have limited treatment options.
In addition to MAT2203, preclinical and clinical data have demonstrated that this novel technology can potentially provide solutions to many challenges of achieving safe and effective intracellular delivery of both small molecules and larger, more complex molecular cargos including small oligonucleotides such as ASOs and siRNA. The combination of its unique mechanism of action and flexibility with routes of administration (including oral) positions Matinas’ LNC technology to potentially become a preferred next-generation orally available intracellular drug delivery platform.
Forward-looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the expected closing date of the offering described in this press release. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate, and management's current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential, "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include, but are not limited to, those set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, as well as other documents filed by the Company from time to time thereafter with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Investor Contact
LHA Investor Relations
Jody Cain
Jcain@lhai.com
310-691-7100
FAQ
What type of offering did Matinas BioPharma Holdings, Inc. (MTNB) announce?
How many shares of common stock were offered in the registered direct offering by Matinas BioPharma Holdings, Inc. (MTNB)?
What is the combined offering price per share and accompanying warrant in the registered direct offering by Matinas BioPharma Holdings, Inc. (MTNB)?
When will the warrants issued in the registered direct offering by Matinas BioPharma Holdings, Inc. (MTNB) be exercisable?
What is the exercise price of the warrants in the registered direct offering by Matinas BioPharma Holdings, Inc. (MTNB)?
